GE invests in second CRO in a year

- Last updated on GMT

GE Capital invests in Syngene
GE Capital invests in Syngene
GE has made its second move in the CRO space in a year by investing in Biocon’s IPO bound contract research unit.

According to a Biocon statement GE Capital – the financial services unit of US conglomerate General Electric – has paid $23m for an 8 per cent stake in Bangalore, India based Syngene.

GE’s investment in Syngene – which values the formulation development and chemistry services firm at around $300m – comes as the Indian services firm prepares to list on an as yet unspecified financial market.

Biocon MD Kiran Mazumdar-Shaw said: “GE Capital’s investment in Syngene, Biocon’s subsidiary, is a validation of our research services business model which has delivered consistent value to our partners as well as other stakeholders​."

Mazumdar-Shaw also said the investment is “a validation of our research services business model [and]…This takes us closer to our commitment of taking Syngene through an IPO at the most opportune time​.” 

Syngene director Peter Bains,was similarly positive, suggesting the additional funds  “will enable Syngene to expand its integrated discovery and development services platform and harness the global outsourcing opportunity to foster high value strategic partnerships with leading pharma and biotech companies.

Besides fueling our future growth, this investment also endorses the quality of innovation at Syngene and the role played by its scientific team in accelerating innovation and productivity of its global customers.​”

CRO space

The investment follows just a few months after GE Healthcare – another unit of General Electric bought genomic services CRO, SeqWright, as part of an effort to build in the personalised medicines space.

Before that the firm – in 2010 – GE acquired biomarkers services and technology firm Clarient to expand its diagnostic imaging business into cancer diagnostics and characterisation.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers